Marielle MD - Daiichi Sankyo Global Devel

All Insiders . USA . 
Stock . Daiichi Sankyo . Stakeholders . Insider . Marielle MD
DSKYF Stock  USD 28.66  0.76  2.72%   

Insider

Marielle MD is Global Devel of Daiichi Sankyo
Phone81 3 6225 1111
Webhttps://www.daiichisankyo.com

Daiichi Sankyo Management Efficiency

The company has return on total asset (ROA) of 0.0209 % which means that it generated a profit of $0.0209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0432 %, meaning that it generated $0.0432 on every $100 dollars invested by stockholders. Daiichi Sankyo's management efficiency ratios could be used to measure how well Daiichi Sankyo manages its routine affairs as well as how well it operates its assets and liabilities.
Daiichi Sankyo has accumulated 143.07 B in total debt with debt to equity ratio (D/E) of 0.12, which may suggest the company is not taking enough advantage from borrowing. Daiichi Sankyo has a current ratio of 3.29, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Daiichi Sankyo until it has trouble settling it off, either with new capital or with free cash flow. So, Daiichi Sankyo's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Daiichi Sankyo sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Daiichi to invest in growth at high rates of return. When we think about Daiichi Sankyo's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Nadim AhmedBristol Myers Squibb
51
Josep CatllaSanofi ADR
N/A
Samir MDNovartis AG ADR
62
MBA DVMAstraZeneca PLC ADR
65
Derica RiceBristol Myers Squibb
56
Josephine FubaraSanofi ADR
N/A
Cari GallmanBristol Myers Squibb
N/A
Patrice BulaNovartis AG ADR
65
Diane WilfongGilead Sciences
62
Karen HaleNovartis AG ADR
56
Chris SheldonAstraZeneca PLC ADR
N/A
Dante BeccariaSanofi ADR
N/A
Gonzalo VinaAstraZeneca PLC ADR
N/A
Paula PriceBristol Myers Squibb
59
Eva SchaeferJansenSanofi ADR
N/A
Deborah EldracherAstraZeneca PLC ADR
59
Robert KowalskiNovartis AG ADR
53
Timothy PowerBristol Myers Squibb
N/A
Tim PowerBristol Myers Squibb
N/A
Jitendra TyagiBristol Myers Squibb
N/A
Paul PenepentNovartis AG ADR
N/A
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company was founded in 1899 and is headquartered in Tokyo, Japan. Daiichi Sankyo operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 16458 people. Daiichi Sankyo [DSKYF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity0.0432
Return On Asset0.0209

Daiichi Sankyo Leadership Team

Elected by the shareholders, the Daiichi Sankyo's board of directors comprises two types of representatives: Daiichi Sankyo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Daiichi. The board's role is to monitor Daiichi Sankyo's management team and ensure that shareholders' interests are well served. Daiichi Sankyo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Daiichi Sankyo's outside directors are responsible for providing unbiased perspectives on the board's policies.
Masahiko Ohtsuki, Executive Officer, Senior Director of Research in Main Research & Development Unit
Junichi Onuma, VP Department
Hiroyuki Okuzawa, Executive Officer and Presidentident of ASCA Company
Hideyuki Haruyama, Co Adviser
Akio Sakurai, Corp Unit
Yoshinori Kaneshima, Corp Unit
Kentaro Asakura, VP Department
Sunao DVM, Group Pres
Naoto Tsukaguchi, Corp Counsel
Takashi Matsumoto, Co HR
Marielle MD, Global Devel

Daiichi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Daiichi Sankyo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0432
Return On Asset0.0209
Profit Margin0.05 %
Operating Margin0.06 %
Current Valuation57.82 B
Shares Outstanding1.92 B
Shares Owned By Insiders1.45 %
Shares Owned By Institutions56.22 %
Price To Earning91.96 X
Price To Book5.85 X

Currently Active Assets on Macroaxis

RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
SSentinelOne
WDWalker Dunlop

Other Information on Investing in Daiichi Pink Sheet

Daiichi Sankyo financial ratios help investors to determine whether Daiichi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Daiichi with respect to the benefits of owning Daiichi Sankyo security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY